Connect with us

Government

HCQ All Over Again: WaPo Trashes Blood Plasma COVID-19 Treatment After Trump Announces Breakthrough

HCQ All Over Again: WaPo Trashes Blood Plasma COVID-19 Treatment After Trump Announces Breakthrough

Published

on

HCQ All Over Again: WaPo Trashes Blood Plasma COVID-19 Treatment After Trump Announces Breakthrough Tyler Durden Tue, 08/25/2020 - 09:09

Authored by Matt Margolis via PJMedia.com,

“Blood from people who recover from coronavirus could provide a treatment,” reported the Washington Post on March 27, just a couple weeks after the World Health Organization declared COVID-19 a pandemic.

Just over a week later, the Washington Post reported again that while there was no vaccine yet for COVID-19, “we do have one potentially promising treatment to help people infected with the coronavirus: infusions of antibody-rich plasma from other patients who have had the disease and recovered.

A couple months later, the Washington Post again touted the potential of blood plasma, also called convalescent plasma, in treating the virus. “A large study of 20,000 hospitalized covid-19 patients who received transfusions of blood plasma from people who recovered found the treatment was safe and suggests giving it to people early in the disease may be beneficial,” they reported June 18, 2020, in an article headlined, “Blood plasma from people who recovered is a safe covid-19 treatment, study says.”

Earlier this month, four former FDA commissioners wrote an op-ed in the Washington Post arguing that “blood plasma might be the COVID-19 treatment we need.”

Flash forward Trump’s announcement that a breakthrough treatment for the coronavirus, convalescent plasma, had been given emergency approval by the Food and Drug Administration (FDA). According to FDA Commissioner Stephen Hahn, plasma treatments reduce mortality of COVID-19 by 35 percent, but, suddenly, the Washington Post isn’t very impressed by blood plasma as a COVID-19 treatment anymore.

“Scientists express doubts about coronavirus treatment touted as breakthrough by Trump” reads the headline on their live updates page Monday afternoon.

The Food and Drug Administration’s decision to give emergency authorization for convalescent plasma as a treatment for novel coronavirus patients — touted as a historic breakthrough by President Trump on Sunday — is raising doubts among some experts who say the therapy hasn’t been adequately tested.

“The urgency of the crisis has elided with a false sense we should skip over rigorous studies of interventions because we don’t have enough time,” Peter Bach, director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, told The Washington Post.

Gee, I wonder why they suddenly had a change of heart.

Michael Caputo, the Health and Human Services Department Assistant Secretary for Public Affairs, noted the sudden change in attitude by the Washington Post on Twitter:

It’s hydroxychlorquine all over again. Hydroxychloroquine has been proven by many studies to reduce mortality of COVID-19, but it’s not being widely used as a treatment in the United States because the media immediately trashed the drug when Trump touted it as a potential gamechanger in the fight against the coronavirus.

Is this really how it’s going to go every time? The media and the Democratic Party demonized hydroxychloroquine immediately after Trump suggested it could be a gamechanger. Countries that are widely using the drug have lower death rates from COVID-19 than those that aren’t. The left’s fear campaign has cost likely thousands of lives but they don’t care because the worse the United States’ death count looks the better chances there are that Trump won’t get reelected.

Will convalescent plasma meet the same fate as hydroxychloroquine? Is the media that desperate to get rid of Trump they’ll scare the public away from treatments that could save their lives?

Read More

Continue Reading

Science

4 Biotech Stocks For Your August 2021 Watchlist

Investors could be shifting their focus to biotech stocks, should you do the same?
The post 4 Biotech Stocks For Your August 2021 Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

top biotech stocks to watch

4 Top Biotech Stocks To Watch This Month

As investors look for the next lucrative industry in the stock market, biotech stocks would often be in sight. It may not be the largest industry nor the most exciting, but it does boast some of the highest potential for returns. For example, a biotech company posting positive clinical trial results or gaining FDA approval will likely see big gains. Meanwhile, a delay or negative results could send a company’s stock in the wrong direction. 

We need to look no further than Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) when it comes to the importance health care brings to the table. Out of the blue, we were struck by a global pandemic that has changed everyone’s lives. This has then made people realize the important roles that biotech stocks play in crucial times like this. Demand for coronavirus vaccines remains high as fears of the delta variant escalate. With the potential need for booster shots in discussion, Moderna and Pfizer are able to raise the prices of their jabs in their latest European Union (EU) supply contracts. With that being said, are you also on the lookout for the top biotech stocks in the stock market today

Top Biotech Stocks To Buy [Or Sell] In August 2021

BioNTech SE

Firstly, we have the German biotech company, BioNTech. Put simply, it develops and commercializes immunotherapies for cancer and other infectious diseases. Over the past year, the company became known globally through its partnership with Pfizer to develop the coronavirus vaccine that is being used today. BNTX stock has skyrocketed over the past month due to fears of coronavirus escalating. It has risen over 45% just within the one-month period. 

In July, the company along with Pfizer announced that the U.S. government purchased an additional 200 million doses of its coronavirus vaccine. With this, the total number of doses supplied by the companies to the U.S. government will be at 500 million. These additional doses are expected to be delivered from October 2021 through April 2022. The U.S. government’s confidence in the vaccine puts both companies in a favorable position. After all, vaccines have been and will remain critical in protecting lives against the pandemic.

On another note, BioNTech has also announced the launch of its Malaria project last Monday. This project aims to develop a well-tolerated and highly effective Malaria vaccine and implement sustainable vaccine supply solutions on the African continent. Its efforts will include cutting-edge research and innovation, investments in vaccine development, and establishing manufacturing facilities across the continent. Given the company’s track record in tackling infectious diseases, there are reasons to believe this will be successful long-term. All things considered, would you consider buying BNTX stock?

biotech stocks (BNTX stock)
Source: TD Ameritrade TOS

Read More

Zai Lab Ltd

China-based biopharmaceutical company Zai Lab focuses on developing and commercializing therapeutics in oncology, autoimmune and infectious diseases. As of now, it has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. A few examples would be Niraparib, Zl-2103, ZL-1101, and others. 

Last Tuesday, the company and Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) announced that patient enrollment in the ATTACK Phase 3 registrational clinical trial of sulbactam-durlobactam is now complete. This will be the largest antibiotic-resistant, pathogen-specific registrational trial conducted globally. Also, it is the first to focus specifically on carbapenem-resistant Acinetobacter infections. Should top-line data be announced in the coming months, it would be a huge step for both companies. 

Besides that, Zai Lab also collaborated with MacroGenics (NASDAQ: MGNX) to develop and commercialize preclinical bispecific antibodies in oncology during its second quarter. Under the terms of the agreement, Zai Lab receives commercial rights in China, Japan, and Korea while MacroGenics will have the rights in all other territories. Now, the collaboration leverages both companies’ unique research capabilities and gives Zai Lab access to MacroGenics’ proprietary technologies to expand its innovative oncology portfolio. With these in mind, would ZLAB stock be a top biotech stock to buy?

best biotech stocks (ZLAB stock)
Source: TD Ameritrade TOS

[Read More] Best Communication Stocks To Watch Right Now

Vertex Pharmaceuticals Incorporated

Next up, we may have one of the top biotech companies that have flown under the radar of many investors, Vertex. For the uninitiated, the company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF). Its marketed medicines are ORKAMBI and KALYDECO. 

Just last week, Vertex announced that it will initiate a Phase 3 development program for the new once-daily investigational triple combination of VX-121/tezacaftor/VX-561(deutivacaftor) in the second half of 2021. The data from its Phase 2 study were mostly encouraging. Hence, the company aims to develop a more effective treatment regimen with the potential to restore cystic fibrosis transmembrane conductance regulator function in people with CF to even higher levels than currently achievable. 

During its second quarter, Vertex showed continued, and significant growth in its CF franchise. Its product revenues came in at $1.79 billion, an increase of 18% year-over-year. Thus, allowing the company to raise its full-year guidance for product revenues to $7.2 to $7.4 billion. Moreover, Vertex has also made important progress with its pipeline programs with five programs in mid to late-stage clinical trials. So, would you consider investing in VRTX stock on the dip? 

VCYT stock
Source: TD Ameritrade TOS

[Read More] Top Gaming Stocks To Buy Now? 4 Names To Watch

Veracyte Inc

Veracyte is a genomic diagnostics company. The company utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, and produces genomic tests. The genomic tests include Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier, and Afirma Xpression Atlas. 

Investors could be watching VCYT stock following the company’s recent new data announcement and second-quarter earnings report. So, Veracyte’s new data suggest the Decipher Prostate Biopsy genomic classifier (GC) may help guide treatment decisions for prostate cancer patients who are candidates for active surveillance (AS). It has found evidence that Decipher scores predict time to definitive treatment and time to treatment failure among men with early-stage prostate cancer. With this, it fills a critical gap in prostate cancer treatment. 

On the other hand, its second-quarter financial results showed significant momentum with particularly strong growth in its thyroid and urologic cancer product lines. Its total revenue was $55.1 million, up by 166% year-over-year. Meanwhile, its total volume of genomic tests grew to 20,856, an increase of 215% compared to the prior year’s quarter. If we take into account the pending HalioDx acquisition, it will further fuel Veracyte’s global cancer diagnostics growth and leadership. So, would you be watching VCYT stock right now?

VCYT stock
Source: TD Ameritrade TOS

The post 4 Biotech Stocks For Your August 2021 Watchlist appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Stocks

Best Cheap Stocks To Buy Now? 4 Tech Stocks To Know

Could these tech stocks be worth betting on now?
The post Best Cheap Stocks To Buy Now? 4 Tech Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Published

on

best cheap stocks to buy now (tech stocks)

Are These The Top Tech Stocks To Buy This Week?

With the current momentum in the broader stock market, investors could be considering tech stocks among other growth areas now. For starters, companies across the board continue to see stellar growth this earnings season. According to global market data analysis firm Refinitiv, overall earnings across the S&P 500 are expected to rise 76% year-over-year. Notably, this would mark its fastest growth since 2009. With the economy having gone into full swing for the past quarter, this would make sense. Now, tech stocks, in particular, could be well-positioned to leverage the current market conditions.

For the most part, the industry does not seem to be slowing down anytime soon as well. Evidently, some of the biggest names in tech known as FAANG stocks reported solid earnings over the past few weeks. To highlight, Amazon (NASDAQ: AMZN) saw significant growth across its wide portfolio. Accordingly, it posted sizable year-over-year jumps of 87% in ad revenue and 37% in cloud revenue. Elsewhere, Microsoft (NASDAQ: MSFT) is reportedly looking to invest in Oyo, one of India’s most valuable startups. Backing the leading budget hotel chain operator in the region would be a unique play by Microsoft. Nonetheless, the company appears keen to broaden its investments and current portfolio.

Overall, these are but two instances of the constant growth in the tech industry now. Most would argue that the stock market today is home to plenty more upcoming tech stocks worth knowing. Should all this have you interested to invest in some yourself, here are four to watch this week.

Best Tech Stocks To Buy [Or Sell] Today

Lam Research Corporation

Lam Research is a tech company that focuses on its innovative wafer fabrication equipment and services. Its products allow chipmakers to build smaller, faster, and better-performing electronic devices. It combines its superior systems engineering capabilities with its unwavering commitment to customer success. In fact, nearly every advanced chip is built with the company’s technology. LRCX stock currently trades at $641.80 as of Monday’s closing bell and is up by over 68% in the past year. On July 28, 2021, the company reported its June 2021 quarter financials.

Firstly, the company posted revenue of $4.15 billion for the quarter, increasing by over 45% year-over-year. Secondly, the company also saw its earnings per share increase by over 70% year-over-year at diluted earnings per share of $7.98. Lam Research says that strong semiconductor demand and rising device complexity are driving higher levels of wafer fabrication equipment investment. It also says that its edge in technology and collaboration with customers positions the company to extend its leadership across all its market segments. The company also ended the quarter with $6 billion in cash and cash equivalents. Given this piece of news, will you consider adding LRCX stock to your watchlist?

top tech stocks (LRCX stock)
Source: TD Ameritrade TOS

Read More

Virgin Galactic Holdings Inc.

Moving on, we have Virgin Galactic, a spaceflight company with headquarters in California and operations in New Mexico. The company runs a commercial spaceflight business, with regular paid passenger service flights scheduled to begin in 2022. SPCE stock closed Monday’s trading session up 6.30% at $31.87 a share. The company will be reporting its second-quarter 2021 financials on August 5, 2021, after the market closes.

On July 11, 2021, company founder Richard Branson and three other employees rode on a flight as passengers, marking the first time a spaceflight company founder has traveled on his own ship into outer space. This successful flight is a landmark achievement for the company and a historic moment for the new commercial space industry. The team behind this successful flight will also open the door for greater access to space for an industry that is still in its infancy. All things considered, will you buy SPCE stock ahead of it popularizing commercial spaceflight?

best tech stocks (SPCE stock)
Source: TD Ameritrade TOS

[Read More] 4 Top E-Commerce Stocks To Consider Buying Right Now

Roblox Corporation

Roblox is a tech company that focuses on video game development. Its tech platform enables billions of users to play, learn and communicate. Furthermore, it empowers its global community of developers who in turn produce its own immersive multiplayer experiences using Roblox Studio. In essence, the company is one of the top online entertainment platforms for audiences under the age of 18. Shares of RBLX stock closed Monday’s trading session at $78.31 apiece.

Last month, the company announced a strategic partnership that will bring more Sony Music (NYSE: SONY) recording artists to the Roblox metaverse. Both companies will work together to develop innovative music experiences for the Roblox community. It will also offer a range of new commercial opportunities for Sony Music artists to reach new audiences and generate new revenue streams around virtual entertainment. The agreement builds on an existing relationship between the two companies that included previous collaborations with big names such as Lil Nas X’s hit virtual performance on Roblox in November 2020. With that being said, will you consider RBLX stock a top tech stock to add to your radar this month?

top tech stocks (RBLX stock)
Source: TD Ameritrade TOS

[Read More] Best Stocks To Invest In 2021? 4 Dividend Stocks To Watch

ContextLogic Inc.

Another emerging name in the tech space to consider now would be ContextLogic or Wish for short. In brief, the company operates via its proprietary e-commerce platform, Wish. Through a combination of tech and data science, Wish helps to facilitate transactions and interactions between buyers and sellers. The Wish platform provides consumers with an “innovative discovery-based mobile shopping experience”. Accordingly, this would appeal to homebound consumers throughout the current pandemic. In terms of scale, Wish serves millions of consumers from over 100 countries across the globe. The company accomplishes this via its network of over half a million merchants.

Now, WISH stock ended Monday’s trading day up a modest 4.37% at $10.41 a share. Could it be worth investing in now? If anything, the company’s latest earnings figures could provide a clearer understanding on this end. Back in May, the company raked in total revenue of $772 million for the quarter. This marks a solid 75% year-over-year surge. Moreover, Wish also saw its core marketplace revenue per active buyer surge by 76% over the same time. Not to mention, the company’s logistics revenue reportedly quadrupled year-over-year. With Wish set to report its second-quarter fiscal next week, would you consider WISH stock a top cheap tech stock to watch now?

WISH stock
Source: TD Ameritrade TOS

The post Best Cheap Stocks To Buy Now? 4 Tech Stocks To Know appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

Government

As the eviction moratorium ends, we need a long-term solution to housing insecurity

The Centers for Disease Control and Prevention’s (CDC) eviction moratorium for the COVID-19 pandemic provided acute relief to people who were struggling to pay rent. That moratorium expired on July 31; however, neither abruptly ending it nor prolonging…

Published

on

By Carl Romer, Andre M. Perry

The Centers for Disease Control and Prevention’s (CDC) eviction moratorium for the COVID-19 pandemic provided acute relief to people who were struggling to pay rent. That moratorium expired on July 31; however, neither abruptly ending it nor prolonging it will solve the problem of housing insecurity, particularly in Black-majority neighborhoods and for low-income, essential workers.

The COVID-19 pandemic’s health and economic impacts hit Black communities hard because of several systemic risk factors, including higher rates of intergenerational housing, neighborhood poverty, and comorbidities. Mass evictions can only worsen outcomes.

A review of the literature published in Social Science & Medicine found broad consensus that evictions have detrimental health effects on households during normal times. Those effects have been exacerbated during the pandemic. While the moratorium delayed the execution of evictions, it was only temporary, and many households who struggled throughout the pandemic now face a high risk of housing insecurity. Although predicting how many renting households cannot pay their rent is difficult in the absence of federal data collection, a historic eviction wave is on the horizon. The Aspen Institute estimated the number of at-risk people to be between 30 million and 40 million.

One avenue for insight into the looming eviction crisis is looking at eviction filings, which the CDC moratorium did not stop. Just like before the pandemic, eviction filings have continued to disproportionately hit Black communities throughout the pandemic in the places we have data for. Using data from Princeton University’s Eviction Lab, we document eviction filings taking place from the week of March 15, 2020, through the week of June 27, 2021. The data is available for five states and 17 cities at the census-tract level.

There were 351,421 eviction filings in these areas during the pandemic. And while Black-majority neighborhoods hold 10% of these cities’ and states’ populations, they accounted for 24% of eviction filings. Comparatively, neighborhoods with less than 1% Black population also account for 10% of these cities’ and states’ populations, but they accounted for 3% of eviction filings. In the chart below, we show the percentage of eviction filings in neighborhoods by share of the Black population.

Fig1

The 351,421 eviction filings is still significantly lower than the 771,748 filings Eviction Lab predicted would have occurred during normal times. This is similar to the finding by RVA Eviction Lab at Virginia Commonwealth University, which found that evictions filings and judgements in Virginia were down 63% and 81%, respectively. This decrease was felt most significantly in Black-majority neighborhoods.

Fig2

The impending eviction crisis also reveals the housing insecurity of members of the working class, whose wages have not kept pace with housing prices. Many of them are also the pandemic’s “essential” workers.

According to the National Low Income Housing Coalition, workers deemed essential—including food service workers, home health aides, cooks and prep workers, and others—have “risked their lives during the pandemic, but don’t get paid enough to afford housing.” These workers have long been essential, but it has taken the COVID-19 pandemic for them to be acknowledged as such, and it is taking businesses even longer to raise wages to compensate them.

Essential and low-wage workers should be compensated enough to reflect the critical roles they play in the economy. The 2021 National Housing Wage—the estimated hourly wage full-time workers must earn enough to afford a modest one-bedroom rental home at the Department of Housing and Urban Development’s (HUD) fair market rent rate without spending more than 30% of their income—is $20.40 per hour. The federal minimum wage, $7.25, is well below that.

California is planning on using $5.2 billion in federal stimulus money to pay 100% of unpaid rent lower-income Californians incurred during the pandemic. The state has also extended its eviction moratorium to September 30. The state of Washington also extended its eviction moratorium to September 30 with some modifications: Beginning August 1, landlords can take action against tenants who are not paying rent or seeking rental assistance as long as they offer tenants a reasonable repayment plan before beginning the eviction process. Lawmakers in Oregon approved a 60-day eviction delay for renters who seek rent assistance.

While these types of eviction-prevention methods are helpful for recipients, they do not address the fundamental issues of America’s long-standing eviction crisis, which will require action on both housing and labor. Rental assistance programs from HUD and the Department of Agriculture are severely underfunded. So-called “right to work” laws in some states constrain labor protections, drive down wages, and make affording and paying rent more difficult. And a recent poll showed that 80% of Americans agree that the federal minimum wage is too low.

Black neighborhoods and low-wage, essential workers will bear the brunt of the coming eviction crisis. But a simple extension of the CDC moratorium isn’t the answer. The eviction crisis won’t be solved if we don’t address why residents have difficulty paying rent to begin with.

Read More

Continue Reading

Trending